PINP as an aid for monitoring patients treated with teriparatide

Bone

Volumn 48, Issue 4, 2011, Pages 798-803

  Tsujimoto, Mika ^a   Chen, Peiqi ^a   Miyauchi, Akimitsu ^b   Sowa, Hideaki ^a   Krege, John H ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Omura Nat Hosp   (Japan)

Author keywords

Biochemical markers of bone turnover; Bone mineral density; Osteoporosis; Procollagen type I N terminal propeptide (PINP); Teriparatide

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN TYPE 1 N TERMINAL PROPEPTIDE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FEMUR NECK; FRACTURE; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ALGORITHMS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; MALE; MONITORING, PHYSIOLOGIC; OSTEOPOROSIS; PLACEBOS; TERIPARATIDE;

EID: 79952703779     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.12.006     Document Type: Article

References (21)

1. IOF The Adherence Gap: Why osteoporosis patients don't continue with treatment. http://www.osteofound.org.
2. Clowes J.A., Peel N.F., Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J. Clin. Endocrinol. Metab. 2004, 89:1117-1123.
3. Eastell R., Krege J.H., Chen P., Glass E.V., Reginster J.Y. Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr. Med. Res. Opin. 2006, 22:61-66.
4. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J. Bone Miner. Res. 2003, 18:1932-1941.
5. Arlot M., Meunier P.J., Boivin G., Haddock L., Tamayo J., Correa-Rotter R., Jasqui S., Donley D.W., Dalsky G.P., Martin J.S., Eriksen E.F. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J. Bone Miner. Res. 2005, 20:1244-1253.
6. McClung M.R., San Martin M.J., Miller P.D., Civitelli R., Bandeira F., Omizo M., Donley D.W., Dalsky G.P., Eriksen E.F. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 2005, 165:1762-1768.
7. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitlak B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 2001, 344:1434-1441.
8. Prevrhal S., Krege J.H., Chen P., Genant H., Black D.M. Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr. Med. Res. Opin. 2009, 25:921-928.
9. Chen P., Satterwhite J.H., Licata A.A., Lewiecki E.M., Sipos A.A., Misurski D.M., Wagman R.B. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J. Bone Miner. Res. 2005, 20:962-970.
10. Chen P., Miller P.D., Delmas P.D., Misurski D.A., Krege J.H. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J. Bone Miner. Res. 2006, 21:1785-1790.
11. Krege J.H., Blumsohn A., Nickelsen T.A., Marin F., Chen P., Eastell R. Testing an algorithm for using PINP to monitor treatment of patients with teriparatide. J. Bone Miner. Res. 2006, 21(Suppl. 1):S302.
12. Miyauchi A., Matsumoto T., Sugimoto T., Tsujimoto M., Warner R.M., Nakamura T. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 2010, 47:493-502.
13. Lu Y., Mathur A.K., Blunt B.A., Gluer C.C., Will A.S., Fuerst T.P., Jergas M.D., Andriano K.N., Cummings S.R., Genant H.K. Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts. J. Bone Miner. Res. 1996, 11:626-637.
14. Gallagher J.C., Rosen C.J., Chen P., Misurski D.A., Marcus R. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 2006, 39:1268-1275.
15. Glover S.J., Eastell R., McCloskey E.V., Rogers A., Garnero P., Lowery J., Belleli R., Wright T.M., John M.R. Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 2009, 45:1053-1058.
16. Rubin M.R., Bilezikian J.P. The anabolic effects of parathyroid hormone therapy. Clin. Geriatr. Med. 2003, 19:415-432.
17. Saag K.G., Zanchetta J.R., Devogelaer J.P., Adler R.A., Eastell R., See K., Krege J.H., Krohn K., Warner M.R. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009, 60:3346-3355.
18. Burshell A.L., Möricke R., Correa-Rotter R., Chen P., Warner M.R., Dalsky G.P., Taylor K.A., Krege J.H. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 2010, 46:935-939.
19. Krege J., Heathman M., Reginster J., Satterwhite J. Increases in serum-terminal propeptide of type I collagen with teriparatide treatment predict increases in lumbar spine bone density 2003.
20. Blumsohn A. The use of biochemical marker of bone turnover to monitor response to therapy: statistics and logic. Bone markers: biochemical and clinical perspectives 2001, 163-165. Published by Martin Dunitz Ltd. R. Eastell, M. Baumann, N.R. Hoyle, L. Wieczorek (Eds.).
21. Chen P., Glass E.V., Krege J.H. Early changes in bone turnover markers (BTMs) predict vertebral strength changes in teriparatide- or alendronate-treated postmenopausal women with osteoporosis 2007.